Biotech Firm Capricor Faces Investor Lawsuits After Hiding Critical Drug Trial Changes

New York, Monday, 3 August 2026.
Capricor Therapeutics faces securities fraud lawsuits for modifying trial analysis plans for its lead drug without FDA agreement, risking regulatory approval and misleading investors about approval prospects.